Education
About Us
Working with TipRanks
Follow Us
Scandinavian Real Heart AB (SE:HEART)
:HEART
RESEARCH TOOLSreports
Top Page
Scandinavian Real Heart AB
(Frankfurt:HEART)
36Underperform
Scandinavian Real Heart AB (HEART) vs. S&P 500 (SPY)
Market Cap
kr35.77M
Dividend YieldN/A
Average Volume (3M)4.88K
Price to Earnings (P/E)―
Beta (1Y)-0.25
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees8
SectorHealthcare
Sector Strength64
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-20.54
Shares Outstanding2,630,408
10 Day Avg. Volume4,993
30 Day Avg. Volume4,880
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scandinavian Real Heart AB Business Overview & Revenue Model
Company DescriptionScandinavian Real Heart AB (HEART) is a Swedish medical technology company focused on developing advanced cardiac assist devices. The company specializes in creating innovative artificial heart solutions designed to improve the quality of life for patients with severe heart diseases. Their flagship product, the Total Artificial Heart, aims to replicate the functionality of a natural heart, providing a life-saving option for patients awaiting heart transplants.
How the Company Makes MoneyScandinavian Real Heart AB primarily generates revenue through the development and commercialization of its Total Artificial Heart technology. This involves securing partnerships with healthcare institutions and medical device distributors who facilitate the adoption and implementation of their products in clinical settings. Additionally, the company may receive funding through grants, research collaborations, and strategic alliances with larger medical technology firms. As the product progresses through clinical trials and regulatory approvals, sales and licensing agreements are expected to become significant revenue streams.
Scandinavian Real Heart AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 | Gross Profit |
| 9.26M | -50.22M | 12.29M | 7.20M | 332.76K | 3.96M | EBIT |
| -34.38M | -68.45M | -13.85M | -10.33M | -8.64M | -7.09M | EBITDA |
| -14.52M | -67.25M | -13.73M | -10.09M | -8.37M | -6.83M | Net Income Common Stockholders |
| -28.03M | -67.98M | -13.99M | -10.48M | -8.82M | -7.29M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 23.72M | 43.30M | 11.26M | 42.67M | 22.45M | 25.42M | Total Assets |
| 83.28M | 102.64M | 119.82M | 117.82M | 78.04M | 66.61M | Total Debt |
| 6.35M | 8.25M | 2.17M | 2.80M | 3.42M | 3.71M | Net Debt |
| -17.36M | -35.05M | -9.09M | -39.88M | -19.04M | -21.70M | Total Liabilities |
| 15.94M | 20.60M | 22.17M | 6.53M | 6.35M | 7.61M | Stockholders Equity |
| 67.34M | 82.04M | 97.65M | 111.29M | 71.69M | 59.00M |
| Cash Flow | Free Cash Flow | ||||
| -33.50M | -26.82M | -31.14M | -29.24M | -24.18M | -24.98M | Operating Cash Flow |
| -8.24M | -25.05M | -7.38M | -9.65M | -9.41M | -7.32M | Investing Cash Flow |
| -24.28M | -1.77M | -23.76M | -19.59M | -14.76M | -17.65M | Financing Cash Flow |
| 12.93M | 58.87M | -276.28K | 49.46M | 21.21M | 46.71M |
Scandinavian Real Heart AB Technical Analysis
Negative
16.00
Price Trends
15.99
Negative
14.95
Negative
18.63
Negative
Market Momentum
-0.17
Negative
47.90
Neutral
67.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HEART, the sentiment is Negative. The current price of 16 is above the 20-day moving average (MA) of 14.58, above the 50-day MA of 15.99, and below the 200-day MA of 18.63, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 47.90 is Neutral, neither overbought nor oversold. The STOCH value of 67.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:HEART.
Scandinavian Real Heart AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr997.81M | 17.66 | 18.74% | ― | 10.46% | 22.82% | |
51 Neutral | $5.20B | 3.26 | -40.34% | 2.93% | 17.68% | 1.94% | |
46 Neutral | kr239.34M | ― | -102.63% | ― | -0.61% | 54.19% | |
45 Neutral | €1.03B | ― | -8.64% | ― | 19.91% | 78.46% | |
39 Underperform | kr86.54M | ― | -51.52% | ― | 955.20% | 47.31% | |
36 Underperform | kr35.77M | ― | ― | ― | ― | ||
23 Underperform | €212.61M | ― | -159.24% | ― | -22.50% | 76.74% |
* Healthcare Sector Average
Performance Comparison
SE:HEART
Scandinavian Real Heart AB
13.60
-42.55
-75.78%
SE:ACARIX
Acarix AB
0.24
<0.01
1.70%
SE:BACTI.B
Bactiguard Holding AB
30.20
-38.00
-55.72%
SE:CRAD.B
C-Rad AB Class B
29.45
-9.05
-23.51%
SE:LXB
Luxbright AB
0.77
-0.22
-21.91%
SE:QLINEA
Q-linea AB
0.04
-0.25
-87.68%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.